Regulatory approval of olaparib for the treatment of advanced ovarian cancer is based on results of a nonrandomized phase II trial of 298 patients with solid tumors and germline BRCA1 or BRCA2 mutations, including 193 patients with recurrent ovarian cancer [72,73]. Here, BRCA1 is linked to ovarian carcinoma.